Home › Research › Biomarkers
The performance of plasma p-tau217 in Black middle-aged and older adults
Gilda E Ennis, Derek Norton, Rebecca E Langhough, Diane C Gooding, Fabu P Carter, Rachael Wilson, Megan Zuelsdorff, Shenikqua Bouges et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025-05
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, cardiovascular disease (CVD), and amyloid- and tau-PET-positive status demonstrated higher p-tau217. Effect sizes (rpb): eGFR <60 group = 0.48, CVD = 0.25, amyloid-PET-positive status = 0.54; tau-PET-positive status = 0.56. Lower eGFR was related to higher p-tau217 when adjusting for amyloid-PET. For abnormal amyloid-PET and tau-PET, p-tau217 exhibited areas under the curve of 0.90 and 0.89, respectively. Plasma p-tau217 showed promise as an Alzheimer's biomarker in Black adults; however, kidney function and CVD should be considered when interpreting levels. HIGHLIGHTS: Plasma tau phosphorylated at threonine 217 (p-tau217) was tested in a sample of Black middle-aged and older adults. Level of p-tau217 was higher in impaired kidney function and cardiovascular disease. Obesity and diabetes were not related to p-tau217. Level of p-tau217 was higher in amyloid- and tau-PET-positive status. Plasma p-tau217 showed good receiver-operating characteristic area under the curve for abnormal amyloid- and tau-PET.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ennis, G. E., Norton, D., Langhough, R. E., Gooding, D. C., Carter, F. P., Wilson, R., et al. (2025). The performance of plasma p-tau217 in Black middle-aged and older adults. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.70288
Vancouver
Ennis GE, Norton D, Langhough RE, Gooding DC, Carter FP, Wilson R, et al. The performance of plasma p-tau217 in Black middle-aged and older adults. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. doi:10.1002/alz.70288. PMID: 40410928.
BibTeX
@article{ennis2025-40410928,
author = {Ennis, Gilda E and Norton, Derek and Langhough, Rebecca E and Gooding, Diane C and Carter, Fabu P and Wilson, Rachael and Zuelsdorff, Megan and Bouges, Shenikqua and others},
title = {{The performance of plasma p-tau217 in Black middle-aged and older adults}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2025},
doi = {10.1002/alz.70288},
pmid = {40410928},
url = {https://doi.org/10.1002/alz.70288}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, cardiovascular disease (CVD), and amyloid- and tau-PET-positive status demonstrated higher p-tau217.
- Effect sizes (rpb): eGFR <60 group = 0.48, CVD = 0.25, amyloid-PET-positive status = 0.54; tau-PET-positive status = 0.56.
- Lower eGFR was related to higher p-tau217 when adjusting for amyloid-PET.
- For abnormal amyloid-PET and tau-PET, p-tau217 exhibited areas under the curve of 0.90 and 0.89, respectively.
- Plasma p-tau217 showed promise as an Alzheimer's biomarker in Black adults; however, kidney function and CVD should be considered when interpreting levels.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants233
- Evidence strengthLow
How this study scored 55/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 31 of the 56 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 233 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40410928) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 31 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 31 of the 56 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.